Advertisement

Topics

IPF call options

09:41 EDT 18 Aug 2017 | BioCentury

How data from FibroGen and Galapagos created $1.4 billion in market value. Plus: Vicarius’ EU path for U.S. biotechs; and why Qiming invested in in-licensing play Antengene.

Original Article: IPF call options

NEXT ARTICLE

More From BioPortfolio on "IPF call options"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...